Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for IceCure Medical (ICCM) over the last 6 years, with Q2 2025 value amounting to $15000.0.

  • IceCure Medical's Gains from Investment Securities fell 6341.46% to $15000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $68000.0, marking a year-over-year decrease of 3818.18%. This contributed to the annual value of $116000.0 for FY2024, which is 3989.64% down from last year.
  • According to the latest figures from Q2 2025, IceCure Medical's Gains from Investment Securities is $15000.0, which was down 6341.46% from $26000.0 recorded in Q1 2025.
  • In the past 5 years, IceCure Medical's Gains from Investment Securities ranged from a high of $18.7 million in Q4 2022 and a low of -$14.9 million during Q1 2023
  • In the last 5 years, IceCure Medical's Gains from Investment Securities had a median value of $27000.0 in 2024 and averaged $1.8 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 130129.29% in 2022, then crashed by 9988.79% in 2023.
  • Quarter analysis of 5 years shows IceCure Medical's Gains from Investment Securities stood at $1.3 million in 2021, then surged by 1301.29% to $18.7 million in 2022, then tumbled by 99.89% to $21000.0 in 2023, then increased by 28.57% to $27000.0 in 2024, then plummeted by 44.44% to $15000.0 in 2025.
  • Its Gains from Investment Securities stands at $15000.0 for Q2 2025, versus $26000.0 for Q1 2025 and $27000.0 for Q4 2024.